Cerebral Hypoxia, Ischemic Stroke
Conditions
Brief summary
The goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.
Interventions
OTHERBlood sampling
Blood sampling will be made to Day 0, Day 3 and to 3 month after inclusion
Sponsors
Fondation Ophtalmologique Adolphe de Rothschild
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
\- For cases, admitted within the first 36 hours of an acute neurological symptom related to : * An ischaemic cerebrovascular accident (iCVA) eligible for a mechanical thrombectomy procedure, * A subarachnoid haemorrhage (SAH, all aetiologies) : patient presenting with at least a modified Fisher scale 3 or 4, * An intra-parenchymal haematoma (IPH) with greatest axis ≥ 20mm or with NIHSS on admission \>4. OR * For control patients, admitted within 7 days of the onset of acute neurological symptomatology related to a clinical diagnosis of transient ischaemic attack (TIA) - based on thorough questioning of the patient on admission - and prior to imaging, with an ABCD2≥ 2 score. * Express consent to participate in the study. * Member or beneficiary of a social security.
Exclusion criteria
* Pre-existing functional and/or cognitive disability * Patient under legal protection. * Pregnant or breastfeeding woman. * Patient with secondary haemorrhagic transformation. Secondary
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biomarker rates at day 0 | 24 hours | Biomarker: Neutro-Plaket aggregates, extra-cellular DNA networks, von Willebrand Factor |
Countries
France
Contacts
CONTACTFrançois DELVOYE
CONTACTAmélie Yavchitz
Outcome results
None listed